../ IS  
┌tgefi­ gŠ­askjal: Lei­beiningar
Skjaln˙mer: RklÝn-592
┌tg.dags.: 02/28/2023
┌tgßfa: 2.0
2.02.02.01 IGF-binding protein 1

Samheiti: IGFBP1, IGFBP-1, Insulin like growth factor binding protein 1,
Hide details for Sřnataka, geymsla og sřnasending Sřnataka, geymsla og sřnasending
Ger­ sřnis : Serum
Sřni teki­ Ý serum glas me­ rau­um tappa me­ geli (gul mi­ja) e­a Ý serum glas me­ rau­um tappa ßn gels (sv÷rt mi­ja) . Litakˇ­i samkvŠmt Greiner

MŠla gl˙kˇsa og ins˙lÝn ß sama tÝma.

Magn: 1 ml ( min 0,2ml)
Geymsla sřnis: KŠlir ef sent samdŠgurs annars frystir.
Sřnasending: Hra­sending Ý stofuhita (ß ■urrÝs)
Hide details for P÷ntunarkˇ­i Ý FlexLabP÷ntunarkˇ­i Ý FlexLab
ANNAđUT


Bei­ni: SAS Peptide Hormones Section clinical lab.docSAS Peptide Hormones Section clinical lab.doc SAS_form_(word_format).docxSAS_form_(word_format).docx
Senda email me­ DHL-slˇ­ um lei­ og pakki fer. Email: gwen.wark@nhs.net / nick.porter@nhs.net MŠling tekur 5 virka daga.
Hide details for Heiti tilvÝsunarannsˇknastofu og heimilisfangHeiti tilvÝsunarannsˇknastofu og heimilisfang
Email: gwen.wark@nhs.net
nick.porter@nhs.net

Dr Gwen Wark PhD, FRCPath
Consultant ClinicaláBiochemist andáScheme Organiser, UK NEQAS Guildford Peptide Hormones scheme
Berkshire and Surrey Pathology Services
SAS Peptide Hormones Section
Clinical Laboratory
Royal Surrey County Hospital
Guildford UK
Surrey GU2 7XX
Telephone: 01483 406715
Fax: 01483 464168

Hide details for HeimildirHeimildir


Insulin-like growth factor binding protein (IGFBP1)
Container:
Insulin-like growth factor binding protein (IGFBP2)
Click here to magnify the image.
Reference Range:See report
Turnaround Time:5 Working days
Description:Insulin-like growth factor binding protein (IGFBP1)
Vessels and Containers:Serum (gold top)
Sample Requirements:Min 0.2 mL
Store frozen unless sent immediately



Frˇ­leikur: IGF-binding protein (IGFBP)-1 is negatively regulated by insulin.
Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.


Ritstjˇrn

Ingibj÷rg Loftsdˇttir
Sigr˙n H PÚtursdˇttir
Gu­mundur Sig■ˇrsson
KristÝn Sigurgeirsdˇttir

Sam■ykkjendur

┴byrg­arma­ur

═sleifur Ëlafsson

┌tgefandi

Sigr˙n H PÚtursdˇttir

Upp »


Skjal fyrst lesi­ ■ann 10/02/2017 hefur veri­ lesi­ 496 sinnum